Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 12 от 222

Набира участници

Nuestro Valor: Increasing Healthier Food Access for Rural Latino Communities Through a Food Retail Intervention

Hispanic Americans Chronic Disease Prevention Cancer Prevention Fruit and Vegetable Consumption

The goal of this clinical trial is to adapt and implement The Value of Our Health (Our Value), a program to promote eating fruit and vegetables, for people living in rural areas. The program will be offered in small, independent grocery stores and delivered by community health workers. The main question this study will answer is: Do customers who shop at stores receiving Our Value eat more fruits and vegetables than customers of other stores?

Начало: 16.04.2026 Край: 01.05.2029 Възраст: от 18 г.

United States University of Washington NCT07490652

Набира участници

Effects of Low-Dye Taping Compared to Calcaneal Taping in Patients With Plantar Fasciitis

Plantar Fascia

Plantar fasciitis is a common musculoskeletal condition characterized by inflammation and microtears of the plantar fascia, leading to heel pain, particularly during initial steps after rest. It negatively impacts gait, mobility, and overall quality of life. Physiotherapy interventions such as stretching, strengthening, electrotherapy, and taping techniques are commonly used for management. Among these, Low-Dye taping and calcaneal taping provide biomechanical support by reducing strain on the plantar fascia and improving foot posture; however, comparative evidence between the two is limited. This study aims to evaluate the effectiveness of Low-Dye taping versus calcaneal taping in reducing pain and improving foot function in patients with plantar fasciitis. A total of 36 participants will be randomly assigned to either intervention group and treated over a two-week period. Outcome measures will include pain (VAS), functional ability (FFI), ankle range of motion (goniometer), and gait analysis, assessed before and after intervention. Data will be analyzed using SPSS v27, with statistical significance set at p \< 0.05.

Начало: 16.04.2026 Край: 15.07.2026 Възраст: 19–44 г.

Pakistan Foundation University Islamabad NCT07544732

Набира участници Фаза 3

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Hypoparathyroidism Endocrine System Diseases Parathyroid Diseases

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

Начало: 16.04.2026 Край: 01.06.2028 Възраст: от 18 г.

United States Ascendis Pharma Bone Diseases A/S NCT07081997

Набира участници Фаза 2/3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary Hyperparathyroidism Parathyroid Cancer Multiple Endocrine Neoplasias Heritable Hyperparathyroidism +1

Background: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with contrast dye to help find them before surgery. Researchers want to know if a different type of scan and a new tracer can make it easier to find the tumors in the parathyroid glands. Objective: To see if PET/MRI and NeuroEXPLORER PET-CT scans with a 18F-FCH tracer are better than existing methods for finding the parathyroid glands. Eligibility: People aged 18 years or older who are scheduled for surgery to remove a parathyroid gland. Design: Participants will have up to 4 clinic or hospital visits. They will be screened. They will have a physical exam and give blood samples. Participants will have a 4-dimensional computed tomography (4D-CT) scan. This is the current way doctors look for parathyroid glands. They will be injected with an iodine-based dye for the 4D-CT scan. They will lie on a padded table that slides into a donut-shaped machine. Participants will have a positron emission tomography (PET)-magnetic resonance imaging (MRI) and NeuroEXPLORER PET-CT scan. For these scans, they will be injected with a radioactive tracer (18F-FCH). They will wait about 30 to 60 minutes for their body to absorb the tracer. They will lie on a padded table that slides into a tube. Their vital signs will be monitored during the scan. Participants will have surgery to remove the target gland. They may need to stay in the hospital for up to 3 nights. Participants will have a follow-up visit 6 months after the surgery. This may be done remotely....

Начало: 16.04.2026 Край: 05.02.2036 Възраст: 18–100 г.

United States National Institute of Diabetes and Digestive and Kidney NCT07444723

Набира участници Фаза 2/3

Visugromab in Cachexia International Trial

Cancer-associated Cachexia

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

Начало: 16.04.2026 Край: 01.12.2030 Възраст: от 18 г.

Bulgaria, France, Norway +3 CatalYm GmbH NCT07112196

Набира участници Фаза 2

An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors

Advanced HR+/HER- breast cancer

Trial status: Authorised Phase II: ORR, BOR, DCR, CBR, PFS and duration of response (DOR) per investigator assessment of RECIST v1.1. Plasma concentrations of GVV858 and derived PK parameters (e.g., AUC, Tmax, and Cmax)., Phase I: Plasma concentrations of GVV858 and derived PK parameters (e.g., AUC, Tmax, Cmax). ORR, BOR, DCR, CBR, and PFS per investigator assessment of response evaluation criteria in solid tumors (RECIST v1.1), or local PCWG3 criteria including PCWG3-modified RECIST v1.1 (prostate cancer patients only). Phase I: Safety: Incidence and severity of dose-limiting toxicities (DLTs), adverse events (AEs) and serious adverse events (SAEs), including changes in lab values, vital signs, electrocardiograms (ECGs). Tolerability: Frequency of dose interruptions, reductions, discontinuations, dose intensity., Phase II: Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in lab values, vital signs, electrocardiograms (ECGs). Tolerability: Frequency of dose interruptions, reductions, discontinuations, dose intensity.

Начало: 16.04.2026 Възраст: от 18 г.

Czech Republic, Denmark, France +3 Novartis Pharma AG 2025-521911-38-00

Набира участници Фаза 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia

Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein FXN. Friedreich’s ataxia is a rare progressive multisystem disease with an incidence that is estimated to be 1:29 +2

Trial status: Authorised SECONDARY: • Difference between participant groups in Clinical Global Impression of Severity (CGI-S) score at study Week 72 compared with baseline, SECONDARY: • Differences between participant groups in scores on physical function tests (Upright Stability Score (USS) Subscale E of the mFARS, 9-hole peg test, and 25-foot walk test) at study Week 72 compared with baseline, SECONDARY: • Differences between participant groups in scores on 1) the Friedreich’s Ataxia Rating Scale – Activities of Daily Living and 2) the fatigue numeric rating scale at study Week 72 compared with baseline, SECONDARY: • Differences between participant groups in left ventricular mass index, measured on echocardiogram, at study Week 72 compared with baseline, SECONDARY: • Differences between participant groups in changes over time in frataxin amount measured in the skin and in the inside of the cheek, SAFETY: • Incidence of side effects and serious side effects happening after receiving nomlabofusp, monitored for the entire study duration, IMMUNOGENICITY: • Incidence of antidrug antibodies (proteins that cause the immune system to fight the drug) throughout the study PRIMARY: • Difference between participant groups (see Study Design Section) on the Modified Friedreich’s Ataxia Rating Scale (mFARS) total score at study Week 72 compared with baseline

Начало: 16.04.2026 Възраст: 18–64 г.

France Larimar Therapeutics Inc. 2025-521628-31-00

Набира участници Фаза 3

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Obesity

Trial status: Authorised Change from baseline in body weight (kg) at Week 64, Change in HbA1c (%) from baseline at Week 64, Occurrence at Week 64 of: o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: o Fasting triglycerides (mg/dL) o Non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84, Change in HbA1c (%) from baseline at Week 84 Percent change from baseline in body weight at Week 64

Начало: 16.04.2026 Възраст: от 18 г.

Bulgaria, Czech Republic, Germany +5 Metsera Inc. 2025-523975-48-00

Набира участници

Comparison of the Effects of Sevoflurane and Desflurane on Optic Nerve Sheath Diameter During Laparoscopic Surgery

Intracranial Pressure Laparoscopic Surgery Optic Nerve Sheath Diameter

Laparoscopic surgeries require pneumoperitoneum and Trendelenburg position, which may lead to increased intracranial pressure (ICP). Optic nerve sheath diameter (ONSD) measurement via ultrasound is a non-invasive method to evaluate ICP. This prospective study aims to compare the effects of sevoflurane and desflurane on ONSD in patients undergoing laparoscopic hysterectomy and bilateral oophorectomy in the Trendelenburg position.

Начало: 15.04.2026 Край: 15.05.2026 Възраст: 18–85 г.

Turkey (Türkiye) Medipol University NCT07525648

Набира участници

MucoLock™ for Treatment of Stomatitis

Stomatitis Pain Burning Mouth Burning Mouth Syndrome +1

The purpose of this research is to test how well people can tolerate MucoLock™ as a treatment for mouth pain or burning sensation and how well it works to reduce mouth pain or burning sensation. Study participants will be asked to use MucoLock™ topical solution as a "swish and spit" solution (similar to mouthwash) three times per day for 5 minutes each time, for 28 days.

Начало: 15.04.2026 Край: 01.05.2028 Възраст: от 18 г.

United States Baptist Health South Florida NCT07506018

Набира участници Фаза 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

Начало: 15.04.2026 Край: 31.03.2031 Възраст: 2–17 г.

Taiwan, Thailand, United Kingdom +1 Hoffmann-La Roche NCT07158242

Набира участници

Ultradian Steroid Rhythms in Adrenal Incidentalomas

Mild Autonomous Cortisol Secretion Adenoma Non Secreting Adenoma

Twenty to 40% of adrenal incidentalomas are responsible for MACS (mild autonomous cortisol producing secretion). The biological tools used in current practice to explore MACS do not provide precise information on cortisol production abnormalities. This study is a comparative analysis of the dynamics/rhythmicity of interstitial cortisol and other steroid concentrations between MACS and non-secreting adenomas (ANS). Using the original and innovative U-RHYTHM system, interstitial fluid samples will be taken every 20 minutes for 24 to 48 hours from patients with MACS or non-secreting adenomas, and steroid assays will be performed in the perfusates to analyze steroid hormone production over 24 hours.

Начало: 15.04.2026 Край: 01.10.2027 Възраст: от 18 г.

France University Hospital, Bordeaux NCT07387419

Набира участници Фаза 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Uterine Sarcoma Uterine Leiomyosarcoma Endometrial Stromal Sarcoma ESS +5

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)

Начало: 15.04.2026 Край: 01.04.2028 Възраст: от 18 г.

United States Dana-Farber Cancer Institute NCT07467772

Набира участници

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

Indolent Systemic Mastocytosis

This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.

Начало: 15.04.2026 Край: 01.12.2032 Възраст: от 18 г.

United States Blueprint Medicines Corporation NCT07264959

Набира участници Фаза 1

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Castration-resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Начало: 15.04.2026 Край: 01.03.2029 Възраст: от 18 г.

United States Janux Therapeutics NCT07545811

Набира участници Фаза 1

Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors

Advanced Malignant Cancer

The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.

Начало: 15.04.2026 Край: 01.12.2028 Възраст: от 18 г.

China Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NCT07482592

Набира участници

Using Virtual Reality to Improve Medical Training

Type 2 Diabetes (T2DM) Geriatric Syndromes Disability Hearing Disability Physical +2

As the U.S. population ages, future physicians must be prepared to care for older adults with multiple health conditions and complex needs. This study will test whether cinematic virtual reality (VR)-an immersive, interactive learning tool-is more effective than traditional lectures in helping medical students learn about geriatric care. Students who complete the VR training will experience realistic patient scenarios that show what can go wrong in medical care and learn how to apply osteopathic principles to improve outcomes. Researchers will compare students' performance on a clinical skills assessment and explore their experiences with the VR training. The goal is to determine whether cinematic virtual reality can better prepare students for residency and improve their ability to provide compassionate, high-quality care for older adults.

Начало: 15.04.2026 Край: 30.06.2027 Възраст: от 18 г.

United States Ohio University NCT07542834

Набира участници Фаза 2

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Extensive Stage Lung Small Cell Cancer

START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.

Начало: 15.04.2026 Край: 01.10.2029 Възраст: от 18 г.

France, Greece, Italy +2 ETOP IBCSG Partners Foundation NCT07203053

Набира участници Фаза 2

Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children

Small Intestine Bacterial Overgrowth

The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.

Начало: 15.04.2026 Край: 01.06.2026 Възраст: 1–2 г.

Bangladesh University of Virginia NCT07451171

Набира участници

GALLVIA Trial: EUS-Guided vs Transpapillary Gallbladder Drainage for Acute Calculous Cholecystitis

Acute Calculous Cholecystitis

This multicenter, prospective, open-label, randomized controlled trial compares endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with endoscopic transpapillary gallbladder drainage (EGBS) in poor surgical candidates with acute calculous cholecystitis. Eligible patients will be randomized in a 1:1 ratio to undergo either EUS-GBD using a lumen-apposing metal stent or EGBS using a transpapillary plastic stent. The primary endpoint is clinical success, defined as successful gallbladder drainage with subsequent improvement of acute cholecystitis without the need for additional gallbladder drainage. Secondary endpoints include technical success, adverse events, reintervention rate, procedure time, length of hospital stay, and 30-day mortality. The trial aims to determine whether EUS-GBD provides superior clinical outcomes compared with EGBS in this high-risk population.

Начало: 15.04.2026 Край: 31.12.2030 Възраст: от 18 г.

Japan Aichi Medical University NCT07536191

1 … 10 11 12 13 14 … 222